SCHEMBL23405505

SCHEMBL23405505

Oc1ccc(-c2cn(-c3cccc(F)c3)nn2)cc1O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.72
▸ SNCA P37840 1/20 0.72
▸ STS P08842 3/20 0.60
▸ HSD17B1 P14061 2/20 0.57
▸ HSD17B2 P37059 2/20 0.57
▸ NOTUM Q6P988 1/20 0.53
▸ CA12 O43570 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ KEAP1 Q14145 4/20 0.46
▸ NFE2L2 Q16236 3/20 0.46
▸ FLT3 P36888 2/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ GSK3B P49841 1/20 0.45
▸ RXRA P19793 2/20 0.44
▸ GRIN1 Q05586 2/20 0.44
▸ GRIN2B Q13224 2/20 0.44
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA5A P35218 1/20 0.43
▸ PTGS2 P35354 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23557798 0.86 HSD17B1 (0.76) MAPTSNCASTSHSD17B1HSD17B2
SCHEMBL23405489 0.85 MAPT (0.78) MAPTSNCASTSHSD17B1HSD17B2
SCHEMBL23430997 0.84 MAPT (0.77) MAPTSNCAHSD17B1HSD17B2CA12
SCHEMBL12682333 0.84 SNCA (1.00) MAPTSNCAHSD17B1HSD17B2CA12
SCHEMBL23405494 0.83 MAPT (0.81) MAPTSNCAHSD17B1HSD17B2FLT3
SCHEMBL23405479 0.82 MAPT (0.78) MAPTSNCASTSHSD17B1HSD17B2
SCHEMBL23405482 0.82 MAPT (0.83) MAPTSNCASTSHSD17B1HSD17B2
SCHEMBL23405495 0.79 MAPT (0.82) MAPTSNCAHSD17B1HSD17B2CA12
SCHEMBL23405476 0.78 MAPT (0.81) MAPTSNCAHSD17B1HSD17B2NOTUM
SCHEMBL18031112 0.78 HSD17B1 (0.81) MAPTSNCASTSHSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297178-B2 Triazole derivative and use thereof GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2025-05-13 — — US claimed
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2024-05-23 — — US claimed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 — — US claimed
US-12297178-B2 Triazole derivative and use thereof GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2025-05-13 — — US disclosed
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2024-05-23 — — US disclosed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 — — US disclosed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF FABP4, LIPC, GPR119 MAPT 2951/4885SNCA 4775/4885STS 646/4885
US-12297178-B2 Triazole derivative and use thereof FABP4, LIPC, GPR119 MAPT 2945/4885SNCA 4771/4885STS 649/4885
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF FABP4, LIPC, GPR119 MAPT 2945/4885SNCA 4771/4885STS 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback